Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;10(7):e637.
doi: 10.1002/iid3.637.

Reduced number of IFN-γ producing cells in peripheral blood is a biomarker for patients with renal cell carcinoma

Kun-Jin Wu  1 , Kun Yang  1 , Feng-Ping Zhang  1 , Si-Nan Liu  1   2 , Kai-Bo Yang  1 , Xiao-Hua Ma  1 , Xing Zhang  1 , Yan-Fen Ma  3 , Hui Geng  4 , Zheng Wang  1 , Chang Liu  1 , Ting Lin  1   2
Affiliations

Reduced number of IFN-γ producing cells in peripheral blood is a biomarker for patients with renal cell carcinoma

Kun-Jin Wu et al. Immun Inflamm Dis. 2022 Jul.

Abstract

Renal cell cancer (RCC) is the most lethal of all the common urologic cancers and constitutes 2.2% of all malignancy diagnoses. The incidence of RCC has been steadily increasing in recent decades. The classic risk factors of RCC include smoking, hypertension, obesity, genetics, and genetic mutations. Recent studies also revealed that RCC was an immunogenic tumor and affected by host immune status. Among the pan-cance, RCC presented with the highest degree of immune infiltration, indicating RCC patients might benefit from immunotherapy. A new immune classification of RCC has been developed by Su et al. based on tumor-infiltrating lymphocytes to guide clinical practice. However, these studies mainly focus on biomarkers derived from tumor microenvironment (TME), the biomarkers based on peripheral blood samples to RCC have rarely been described. We collected peripheral blood samples from RCC patients and their matched healthy controls and detected the number of IL-2 and IFN-γ producing cells by implementing an enzyme-linked immunospot (ELISPOT) assay. This is the first study to report blood-based immune biomarkers for RCC using an ELISPOT assay. Our results suggested the frequency of IFN-γ producing cells but not IL-2 producing cells was associated with RCC risk. These findings warrant further validation in larger prospective studies.

Keywords: T cells; animals; cells; cytokines; human; molecules; thelper cells (Th1/Th2/Th17).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

References

    1. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79‐87. - PMC - PubMed
    1. Yong C, Stewart GD, Frezza C. Oncometabolites in renal cancer. Nat Rev Nephrol. 2020;16(3):156‐172. - PMC - PubMed
    1. Wang Y, Zhang Y, Wang P, Fu X, Lin W. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Mol Cancer. 2020;19(1):149. - PMC - PubMed
    1. Diaz‐Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16(12):721‐735. - PubMed
    1. Hu H, Chen Y, Tan S, et al. The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol. 2022;13:802846. - PMC - PubMed

Publication types